Weekly Paclitaxel in Combination with Bevacizumab in Patients with Non-Squamous Non-Small Cell Lung Cancer Previously Untreated -A Phase II study-

Weekly Paclitaxel in Combination with Bevacizumab in Patients with Non-Squamous Non-Small Cell Lung Cancer Previously Untreated -A Phase II study- - Weekly Paclitaxel in Combination with Bevacizumab in Patients with Non-Squamous Non-Small Cell Lung Cancer Previously Untreated -A Phase II study-

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014345

Enrollment

Registered

2014-06-23

Start date

2014-06-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with non-squamous non-small cell lung cancer previously untreated

Interventions

Weekly Paclitaxel in combination with Bevacizumab in patients with non-squamous non-small cell lung cancer previously untreated

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Histological or cytological diagnosis of non-squamous NSCLC (2)Provided written consent in person for participation in this study (3)Age 20 years or older (4)ECOG Performance Status (PS) 0 to 2 (5)Life expectancy of more than three months (6)Have measurable lesions according to the Response Evaluation Criteria in Solid Tumors ver1.1 (7)Have adequate function of major organs (bone marrow, liver, kidneys) defined as follows: Neutrophils>=1,500 /mm3 Platelets>=100,000 /mm3 Hemoglobin>8.0 g/dl AST and ALT<=100IU/l Serum creatinine<=1.5 mg/dl (8)one prior chemotherapy excluded adjuvant chemotherapy, EGFR-TKI and ALK inhibitor (9)no administration of Paclitaxel previously

Exclusion criteria

Exclusion criteria: (1)Received transfusion or G-CSF within 14 days prior to enrollment (2)Urine protein>=2+ (3)History of drug allergy (4)Active multiple cancers (5)Severe infection (6)High fever (7)Abnormal cardiac function (8)Severe pulmonary disease; Interstitial pneumonia, severe COPD, pulmonary thromboembolism (9)History of hematoemesis, ileus and gastroduodenal ulcer (10)Need for drainage of pleural effusion, acsites or pericardial effusion (11)Medically uncontrolled thromboembolism (12)Symptomatic CNS metastases previously untreated (13)CNS or Psychological disorders (14)Medically uncontrolled hypertension or diabetes mellitus (15)Nonhealing wound and surgery within 4 weeks before treatment (16)History of hemoptysis; one-half teaspoon of bright red blood per event (17)Recent use of aspirin (>=325 mg/day) (18)Severe bone marrow suppression (19)Pregnancy or lactation

Design outcomes

Primary

Measure	Time frame
Progression free survival	—

Secondary

Measure	Time frame
Safety, Disease control rate, Overall response rate, Time to treatment failure, Overall survival	—

Countries

Japan

Contacts

Public ContactMasahiro Kodani

Faculty of Medicine, Tottori University Division of Medical Oncology and Molecular Respirology

kodani@med.tottori-u.ac.jp0859-38-6537

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026